Creo Medical Group (LON:CREO) Hits New 52-Week Low – Should You Sell?

by · The Cerbat Gem

Creo Medical Group PLC (LON:CREO – Get Free Report) shares reached a new 52-week low on Monday . The stock traded as low as GBX 19.86 ($0.26) and last traded at GBX 20.02 ($0.26), with a volume of 4276025 shares traded. The stock had previously closed at GBX 20.45 ($0.27).

Creo Medical Group Trading Down 2.1 %

The firm’s 50-day moving average price is GBX 26.82 and its 200-day moving average price is GBX 31.54. The company has a market cap of £72.42 million, a P/E ratio of -333.65 and a beta of 0.86. The company has a quick ratio of 2.19, a current ratio of 3.24 and a debt-to-equity ratio of 29.96.

Insiders Place Their Bets

In related news, insider Kevin Crofton bought 2,916,666 shares of Creo Medical Group stock in a transaction on Monday, October 21st. The stock was acquired at an average price of GBX 24 ($0.31) per share, with a total value of £699,999.84 ($914,076.57). Company insiders own 22.43% of the company’s stock.

About Creo Medical Group

(Get Free Report)

Creo Medical Group PLC, through its subsidiaries, researches, develops, manufactures, and sells medical devices and instruments in the United Kingdom. It is developing CROMA, an energy platform that combines bipolar radiofrequency for precise localized cutting and microwave energy for controlled coagulation, to provide physicians with flexible, accurate, and highly controllable devices delivered through a flexible endoscope.

Featured Articles